Anthropic's robust financial position and rapid scaling make near-term bankruptcy highly improbable in trader assessments. The company secured a $65 billion Series H round in May 2026 at a $965 billion post-money valuation, pushing annualized revenue run rate past $47 billion with 14-fold year-over-year growth and positive adjusted operating income for consecutive quarters. It is finalizing a $15 billion pre-IPO credit facility while advancing Claude models, including AI-assisted R&D where the system now leads 26% of internal work, alongside enterprise partnerships such as the recent Novo Nordisk collaboration for drug discovery. Preparations for an October 2026 IPO, massive compute commitments exceeding $500 billion, and ongoing model releases further underscore capital access and competitive momentum that would require extraordinary reversals to threaten solvency.